You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

1712 Results
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Cemiplimab - In Combination with Chemotherapy for First-Line Treatment of Advanced Non-Small Cell Lung Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PACLitaxel,
CARBOplatin,
cemiplimab
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
May 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    osimertinib - In combination with pemetrexed and platinum-based chemotherapy for the treatment of locally advanced or metastatic non-small cell lung cancer (NSCLC), based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pemetrexed,
CARBOplatin,
osimertinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2025
Regimen
Cancer Type:
Gynecologic, 
Endometrial
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative, Palliative
Drugs Used:
durvalumab (Compassionate),
PACLitaxel,
CARBOplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jun 2025
Regimen
Cancer Type:
Lung, 
Non-Small Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
amivantamab (Unfunded),
lazertinib (Unfunded)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jul 2025
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
ODB - General Benefit
    prednisone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
prednisone,
riTUXimab (Unfunded),
polatuzumab vedotin (Unfunded),
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Head and Neck, 
Squamous Cell
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Curative
Funding:
New Drug Funding Program
    Pembrolizumab - (Neo)adjuvant Treatment for Resectable Locally Advanced Head and Neck Squamous Cell Carcinoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
pembrolizumab,
CISplatin
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Feb 2026
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Drugs Used:
cetuximab (Unfunded),
irinotecan,
leucovorin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2026
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
DOCEtaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Breast
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
New Drug Funding Program
    Pertuzumab with Trastuzumab (Biosimilar) - Unresectable Locally Recurrent or Metastatic Breast Cancer
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
PERTuzumab,
trastuzumab,
PACLitaxel
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Sep 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's Low Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
New Drug Funding Program
    Obinutuzumab - In Combination with Chemotherapy for Refractory Follicular Lymphoma
ODB - General Benefit
    prednisone
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
oBINutuzumab,
prednisone,
vinCRIStine,
DOXOrubicin,
cyclophosphamide
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Nov 2023
Regimen
Cancer Type:
Gastrointestinal, 
Esophagus, 
Gastric / Stomach
Show More Show more tags
, Show Less Show fewer tags
Intent: Adjuvant, Palliative
Drugs Used:
CISplatin,
fluorouracil
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Aug 2017

Pages